Overview AZD1981 Midazolam CYP4503A Induction Study Status: Completed Trial end date: 2009-04-01 Target enrollment: Participant gender: Summary The primary objective of the study is to investigate if the exposure of midazolam is clinically significantly changed by 14 days of exposure to AZD1981 through possible enzyme induction of CYP3A. Phase: Phase 1 Details Lead Sponsor: AstraZenecaTreatments: Midazolam